Detalles de la búsqueda
1.
Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials.
Am J Physiol Gastrointest Liver Physiol
; 316(3): G372-G386, 2019 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30495974
2.
Assessment of plasma acylcarnitines before and after weight loss in obese subjects.
Arch Biochem Biophys
; 606: 73-80, 2016 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27444119
3.
Effect of two dietary fibers on satiety and glycemic parameters: a randomized, double-blind, placebo-controlled, exploratory study.
Nutr J
; 13: 45, 2014 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-24886409
4.
Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors).
Diabetes Obes Metab
; 20(2): 233-237, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28842950
5.
Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.
Xenobiotica
; 43(6): 498-508, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23256625
6.
MRI assessment of drug-induced fluid accumulation in humans: validation of the technology.
Magn Reson Imaging
; 26(5): 629-37, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18420368
7.
A Systematic Review of Biomarkers and Risk of Incident Type 2 Diabetes: An Overview of Epidemiological, Prediction and Aetiological Research Literature.
PLoS One
; 11(10): e0163721, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27788146
8.
Weight and Glucose Reduction Observed with a Combination of Nutritional Agents in Rodent Models Does Not Translate to Humans in a Randomized Clinical Trial with Healthy Volunteers and Subjects with Type 2 Diabetes.
PLoS One
; 11(4): e0153151, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27093610
9.
Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers.
Adv Ther
; 32(7): 650-61, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26160357
10.
Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects.
J Clin Transl Endocrinol
; 1(1): e3-e8, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29235586
11.
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
PLoS One
; 9(4): e92494, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24699248
12.
Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.
PLoS One
; 9(7): e100778, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24988476
13.
Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 Diabetes.
Clin Pharmacol Drug Dev
; 2(3): 213-22, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27121782
14.
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
BMC Pharmacol Toxicol
; 14: 26, 2013 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-23668634
15.
Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes.
Diabetes Care
; 35(11): 2198-200, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23011728
16.
Reduced T2* values in soleus muscle of patients with type 2 diabetes mellitus.
PLoS One
; 7(11): e49337, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23189142
17.
Assessment of acute and chronic pharmacological effects on energy expenditure and macronutrient oxidation in humans: responses to ephedrine.
J Obes
; 20112011.
Artículo
en Inglés
| MEDLINE | ID: mdl-20847897
18.
Quantitative magnetic resonance (QMR) for longitudinal evaluation of body composition changes with two dietary regimens.
Obesity (Silver Spring)
; 18(2): 391-6, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19696753
19.
Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study.
J Clin Pharmacol
; 50(6): 636-46, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20200268
20.
Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus.
J Clin Pharmacol
; 50(6): 623-35, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20056803